GSK PE Ratio 2010-2022 | GSK
Current and historical p/e ratio for GSK (GSK) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. GSK PE ratio as of March 20, 2023 is 9.21.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| GSK PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-03-20 |
34.93 |
|
4.07 |
| 2022-12-31 |
34.80 |
$8.58 |
4.06 |
| 2022-09-30 |
28.85 |
$8.16 |
3.54 |
| 2022-06-30 |
52.78 |
$3.02 |
17.48 |
| 2022-03-31 |
52.40 |
$3.46 |
15.13 |
| 2021-12-31 |
52.28 |
$3.00 |
17.43 |
| 2021-09-30 |
44.74 |
$2.95 |
15.17 |
| 2021-06-30 |
46.06 |
$2.96 |
15.55 |
| 2021-03-31 |
40.73 |
$3.41 |
11.94 |
| 2020-12-31 |
41.24 |
$3.68 |
11.22 |
| 2020-09-30 |
41.61 |
$4.06 |
10.24 |
| 2020-06-30 |
44.56 |
$4.21 |
10.58 |
| 2020-03-31 |
40.92 |
$3.43 |
11.95 |
| 2019-12-31 |
50.09 |
$2.98 |
16.84 |
| 2019-09-30 |
44.98 |
$2.93 |
15.38 |
| 2019-06-30 |
41.70 |
$2.90 |
14.38 |
| 2019-03-31 |
43.03 |
$2.59 |
16.63 |
| 2018-12-31 |
38.77 |
$2.43 |
15.99 |
| 2018-09-30 |
40.28 |
$1.26 |
31.91 |
| 2018-06-30 |
39.94 |
$1.14 |
35.11 |
| 2018-03-31 |
38.23 |
$0.71 |
53.65 |
| 2017-12-31 |
34.10 |
$0.99 |
34.53 |
| 2017-09-30 |
38.47 |
$1.53 |
25.23 |
| 2017-06-30 |
40.35 |
$1.25 |
32.28 |
| 2017-03-31 |
39.00 |
$1.04 |
37.59 |
| 2016-12-31 |
35.13 |
$0.59 |
59.80 |
| 2016-09-30 |
38.89 |
$0.15 |
259.30 |
| 2016-06-30 |
38.68 |
$0.04 |
1031.34 |
| 2016-03-31 |
35.76 |
$0.48 |
75.29 |
| 2015-12-31 |
34.51 |
$6.56 |
5.26 |
| 2015-09-30 |
32.45 |
$7.64 |
4.25 |
| 2015-06-30 |
34.70 |
$7.55 |
4.60 |
| 2015-03-31 |
37.95 |
$8.01 |
4.74 |
| 2014-12-31 |
34.63 |
$2.29 |
15.14 |
| 2014-09-30 |
36.75 |
$3.54 |
10.39 |
| 2014-06-30 |
42.18 |
$4.00 |
10.55 |
| 2014-03-31 |
41.66 |
$4.24 |
9.83 |
| 2013-12-31 |
41.08 |
$4.43 |
9.28 |
| 2013-09-30 |
38.15 |
$3.09 |
12.36 |
| 2013-06-30 |
37.59 |
$3.20 |
11.75 |
| 2013-03-31 |
34.91 |
$3.38 |
10.34 |
| 2012-12-31 |
31.87 |
$3.68 |
8.67 |
| 2012-09-30 |
33.44 |
$3.94 |
8.49 |
| 2012-06-30 |
32.59 |
$4.10 |
7.95 |
| 2012-03-31 |
31.73 |
$3.99 |
7.96 |
| 2011-12-31 |
31.66 |
$4.11 |
7.70 |
| 2011-09-30 |
28.29 |
$2.60 |
10.88 |
| 2011-06-30 |
29.05 |
$2.50 |
11.62 |
| 2011-03-31 |
25.69 |
$1.40 |
18.35 |
| 2010-12-31 |
25.82 |
$1.21 |
21.29 |
| 2010-09-30 |
25.69 |
$3.05 |
8.42 |
| 2010-06-30 |
21.82 |
$3.15 |
6.93 |
| 2010-03-31 |
24.41 |
$4.54 |
5.38 |
| 2009-12-31 |
26.37 |
$4.34 |
6.08 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$73.444B |
$36.279B |
|
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
|
